Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, latanoprost (Xalatan®) cannot be endorsed for use within NHS Wales for the reduction of elevated intraocular pressure in paediatric patients with elevated intraocular pressure and paediatric glaucoma. |
||
|
||
Medicine details |
||
| Medicine name | latanoprost (Xalatan®) | |
| Formulation | 0.005% eye drops | |
| Reference number | 1179 | |
| Indication | Reduction of elevated intraocular pressure in paediatric patients with elevated intraocular pressure and paediatric glaucoma |
|
| Company | Pfizer Ltd | |
| BNF chapter | Eye | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 11/10/2011 | |